Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.50 |
| ▸ | CHKA | P35790 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675278 | 0.94 | HTR3A (0.47) | NCF1CHKACA2PRMT6HTR3A | |
| Hydrochloric Acid SCHEMBL5009806 | 0.92 | HTR3A (0.46) | NCF1CHKACA2PRMT6HTR3A | |
| SCHEMBL10254779 | 0.86 | AOC3 (0.54) | AOC3OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL5010436 | 0.84 | AOC3 (0.52) | AOC3OPRM1OPRK1 | |
| SCHEMBL10254758 | 0.84 | AOC3 (0.55) | AOC3 | |
| Hydrochloric Acid SCHEMBL5008435 | 0.83 | AOC3 (0.53) | AOC3OPRM1OPRK1 | |
| SCHEMBL6222902 | 0.82 | AOC3 (0.46) | HTR3AAOC3HRH4HRH3TLR7 | |
| SCHEMBL1285548 | 0.80 | GRIN2D (0.50) | HTR3AHRH4HRH3 | |
| SCHEMBL2759552 | 0.80 | HRH4 (0.49) | HTR3AHRH4HRH3TLR7 | |
| SCHEMBL2826503 | 0.79 | KDM4E (0.52) | AOC3OPRM1OPRK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2475653-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029537-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | TPMT, BPHL, VHL | NCF1 1038/4885CHKA 3448/4885CA2 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.